Work

Safety and efficacy of catheter-based renal denervation for the management of resistant hypertension: clinical, imaging and immunological assessment.

Year: 2022
Type: dissertation
Abstract: Hypertension (HT) is the most common modifiable cardiovascular risk factor and is responsible for significant mortality and morbidity. It is estimated that 30-45% of the adult population has HT, with its prevalence increasing with advancing age. The employment of lifestyle changes and drug therapy reduces the risk of major cardiovascular events such as acute myocardial infarction, stroke and heart failure and increases life-expectancy. However, despite the availability of safe and efficacious anti-hypertensive drugs, the prevalence of uncontrolled HT continues to rise, with non-adherence to therapy being the most important contributor of poor blood pressure control. HT is considered true resistant when a documented failure to achieve blood pressure guideline-recommended targets is observed and, secondary HT, non-adherence and pseudo-hypertension have been excluded. The pathophysiology of resistant HT is complex and not clear. The vasoconstrictor effects of the sympathetic nervous system and its implication on the pathogenesis of refractory hypertension have long been known, turning it into an attractive therapeutic target. Renal denervation (RDN) is a minimally invasive percutaneous technique which consists on the delivery of radiofrequency energy on the renal artery wall in order to achieve a selective disruption of sympathetic nerve endings. First generation randomized trials were rather controversial, specifically HTN-3, given the results were not the expected and renal denervation did not achieve a higher blood pressure reduction than the control arm. Several questions have been raised by this ‘negative’ study and prompted investigation around the technique. Up to the current date, RDN has been employed to treat patients with resistant HT and second generation trials have included a wider cohort of patients, in order to assess safety and efficacy of the procedure, based on the development of more advanced devices and the recent knowledge regarding renal nerve distribution. In the current study, we used RDN to treat patients with true resistant HT, in order to assess i) the safety of the technique, through the performance of intra-arterial optical coherence tomography (OCT) in a porcine model and, its efficacy through the histologic evaluation of the treated renal artery; ii) the impact of the technique on the sympathetic cardiac innervation, in a subgroup of patients; iii) the impact of the technique in the immune system and, possibly, identify a biomarker to predict response; iv) the efficacy of the technique through a clinical evaluation and ambulatory blood pressure monitoring v) the impact of renal denervation on several parameters such as left ventricular ejection fraction, diastolic function, arrhythmic profile, renal function, glycemic and lipid profiles, NT pro-BNP and vitamin D. In the first part of our research, we performed unilateral pre-bifurcation RDN, with a multi-electrode (second generation) catheter, in twelve domestic pigs. The contralateral artery was untreated (control). OCT was performed pre and immediately post procedure and follow-up with renal angiogram and OCT was performed after one month. We demonstrated that RDN caused acute vessel wall changes (intimal disruption (edema/spasm) and intraluminal thrombus formation) visible by OCT but, after one month, the vessel was completely healed, with no evidence of renal stenosis in any of the treated subjects. The histological analysis revealed nearly absent tyrosine hydroxylase immunostaining and a statistically significant increase in the amount of collagen fibers in the denervated artery, compatible with a decrease in nerve terminals and an increase in fibrosis, compared to the control, suggesting an efficacious delivery of the radiofrequency energy to the vessel wall. No differences were found in the norepinephrine or epinephrine renal tissue levels between the treated and contralateral kidney. Subsequently, we performed 123I-labelled meta-iodobenzylguanidine (MIBG) cardiac scintigraphy, in a subgroup of patients, before and six months after RDN, to evaluate the impact of the procedure on cardiac sympathetic activity. Early heart to mediastinum ratio (HMR) was significantly lower in responders at baseline but similar after six months follow-up. Late HMR was statistically similar in both groups pre- and post RDN but reduced in comparison to values reported in healthy subjects. Accordingly, there were no statistically significant differences regarding the washout rate but above normal baseline values were detected, a difference more evident in the non-responders (sympathetic overdrive? increased risk of cardiovascular events?), with both group values converging after the RDN. None of the evaluated rates altered significantly at follow-up, translating an absence of deleterious sympathetic nerve disruption. In conclusion, RDN is a safe procedure, in terms of cardiac nerve integrity, but none of the evaluated MIBG parameters were useful to predict response. In the third part our research, we investigated the cellular immune profile in our cohort of 23 patients with resistant HT and treated with RDN. A preliminary assay, which included an extended analysis of T, B and natural killer cells, monocytes and dendritic cells, guided the forthcoming study in order to select T cells (CD4 and CD8, memory and activated subsets) as possible biomarkers of response to RDN. Blood samples were obtained in six timings, pre and post procedure. Response to RDN was evaluated at six-months and one year and was observed in 69.6 and 82.6% of patients, respectively. Absolute values of HLA-DR+ double negative T cells were significantly lower in the group of responders at one year. Additionally, interaction between the timings were found in three T cell subsets (T CD4, T CD8 and naïve T CD8 cells), with the responders tending to present with lower absolute values and little inter-timing variation. Afterwards, our research focused on investigating the behavior of cytokines in 21 RDN patients. We analyzed 45 protein targets which included cytokines, chemokines and growth factors. Response to RDN was evaluated as described previously. Venous blood samples were obtained at four timings, pre and post procedure. 66.7% of the patients were responders at six months and 85.7% were late-responders. Levels of regulated on activation, normal T cell expressed and secreted (RANTES) were significantly lower in responders, both at baseline and at 30 days (p=0.037). As there is evidence that Angiotensin II inhibits RANTES expression and, the renin-angiotensin-aldosterone system is directly linked to the sympathetic nervous system, we could hypothesize that low levels of RANTES are associated with higher levels of angiotensin II and therefore to an over activated sympathetic nervous system, turning these patients more prone to a RDN response. Finally, we assessed serum vitamin D concentration as a predictor of blood pressure response to RDN. Additionally, we evaluated overall long-term safety and efficacy, as well as echocardiographic parameters, in the cohort of 24 patients submitted to RDN. Response at six-months (early-responders) and one year was evaluated. We observed that responders at six-months had significantly higher baseline and six-month follow-up values of vitamin D than non-responders. Responders at one year (including late-responders) continued to present with higher vitamin D levels than non-responders, although it didn’t reach statistical significance, probably due to the low number of the later at this stage. In the long-term follow-up (mean 52 months), 70.8% of the patients maintained a clinical response. Regarding echocardiographic parameters, there was an improvement in diastolic function in non-responders, finding that could reflect benefit from the RDN, even though no effect on blood pressure was observed. No other relevant echocardiographic differences were found. In conclusion, RDN effectively lowered the blood pressure in the majority of the studied patients, with an optimal safety pattern. Our study contributed to better comprehend the clinical, immunological and hemodynamic profiles of patients submitted to this procedure and, to identify potential biomarkers of denervation success. Our findings may allow for a better identification of patients who could really derive benefit from RDN and prompt further investigation around this area.
Author: Silva, Joana Sílvia Delgado
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W6996339358
Cites: 220
Cited by:
Related to: 10